WEB SEARCH


TOP SELECTION

CONTACT US

info_demofinance@mynasdaq.it

DONATION

All profits of this web site are donated to charity 'the arsenal of peace'. VISIT THE WEBSITE

ADS

Complete financial analysis of VICAL INC (VICL)

Name VICAL INC
Year low 2.22
Year High 5.30
Symbol VICL
Last trade 2.81
Percentage change -1.06
Volume 14,617
Media Volume (3m) 740,025
PE Ratio 135.24
EPS 0.021
Market Cap 241
Media fatt 53
Trend fatt trend fatt graph for VICAL INC
Media net income 0
Trend net income trend net income for VICAL INC
P / E P / E graph for VICAL INC - 0 points 0
EPS EPS graph for VICAL INC - 4 points 4
MARKET CAP / TOTAL REVENUE market  cap  /  total  revenue  graph for VICAL INC - 0 points 0
TOT REV 1 / TOT REV 2 TOT REV 1 / TOT REV 2 graph for VICAL INC - 11 points 11
NET INC 1 / NET INC 2 NET INC 1 / NET INC 2 graph for VICAL INC - 12 points 12
MED NET INC / MED TOT REV MED NET INC / MED TOT REV graph for VICAL INC -  points
NET INCOME / MARKET CAP NET  INCOME  /  MARKET  CAP graph for VICAL INC -  points
TOTALREV1/TOTALREV3 totalRev1/totalRev3 graph for VICAL INC - 0 points 0
NET INC1/NET INC3 net inc1/net inc3 graph for VICAL INC - 0 points 0
TOT REV 2/ TOT REV 3 tot rev 2/ tot rev 3 graph for VICAL INC - 0 points 0
NET INC 2 / NET INC 3 net inc 2 / net inc 3 graph for VICAL INC - 0 points 0
. . graph for VICAL INC - 0 points 0
MARKET CAP / NET TANGIBLE ASSETS MARKET CAP / NET TANGIBLE ASSETS graph for VICAL INC - 2 points 2
MARK CAP/TOT STOCK EQ MARK CAP/TOT STOCK EQ graph for VICAL INC - 2 points 2
MARKET CAP / TOT CURRENT ASSETS market cap / tot current assets graph for VICAL INC - 1 points 1
TOT CURR ASSETS / TOT LIAB TOT CURR ASSETS / TOT LIAB graph for VICAL INC - 3 points 3
. . graph for VICAL INC - 0 points 0
SELL HOLD BUY SELL           HOLD          BUY graph for VICAL INC - 0 points 0
SINTESE 35

GRAPHS

max price logarithm graph for VICAL INC based on no conditions max volume linear graph for VICAL INC based on no conditions

News

Vical Reports Prophylactic and Therapeutic Efficacy With Herpes Simplex Vaccines... (Oct 03 - reuters) Vical's Allovectin-7: Are The Phase 3 Trial Results Hiding In Plain Sight? (Sep 30 - reuters) Biotech Stock Mailbag: Research Backs Shorting Micro-Cap Cancer Drug Stocks (Sep 30 - reuters) Why Did My Stock Just Die? (Sep 24 - reuters) Global Situation & Resulting Influences - Research Report on Vical Incorporated and Life Technologies Corp. (Sep 22 - reuters) Allovectin(R) Demonstrates Synergistic Efficacy With Anti-CTLA-4 Antibody in Melanoma... (Sep 22 - reuters) Adjuvants May Hold Key To Unlocking Cancer Immunotherapy Revolution (Sep 21 - reuters) Vical Announces Key International Patents for Vaxfectin(R) Adjuvant (Sep 19 - reuters) Vical to Present at September Investor Conferences (Aug 31 - reuters) Vical: Making Progress In The Area Of HSV-2 Vaccines (Aug 27 - reuters) Vical Provides Vaxfectin(R) Review at Novel Vaccines: Adjuvants & Delivery Systems... (Aug 17 - reuters) Vical to Present at Canaccord Genuity Growth Conference (Aug 08 - reuters) Vical's CEO Discusses Q2 2011 Results - Earnings Call Transcript (Aug 04 - reuters) Vical Reports Second Quarter 2011 Financial Results and Progress in Key Development... (Aug 03 - reuters) 11 Stocks Under $5 With Recent Winning Streaks (Aug 02 - reuters) Vical Announces News Release and Conference Call Schedule for Second Quarter 2011... (Jul 27 - reuters) Vical Announces Early Termination of Hart-Scott-Rodino Waiting Period for TransVax(TM)... (Jul 25 - reuters) 6 Biotech Stocks With 150% Average Yearly Return and Still Climbing (Jul 21 - reuters) Vical Reports Successful Nonclinical Results With Vaxfectin(R) Adjuvant (Jul 21 - reuters) Second Quarter Healthcare Sector Big Winners that are Worth Buying (Jul 20 - reuters) Vical's Uptrend Shows a Strong Heartbeat (Jul 19 - reuters) 5 Healthcare Stocks of Interest This Week (Jul 16 - reuters) » More VICL.W Market Views (Jul 15 - reuters) » More VICL.A Market Views (Jul 15 - reuters) UPDATE 1-Vical to develop DNA vaccine with Japan's Astellas (Jul 15 - reuters) Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus... (Jul 14 - reuters) Vical Announces Scientific Advances for Multiple Programs at DNA Vaccines 2011 Conference (Jul 14 - reuters) One Biotech Stock to Avoid (Jul 14 - reuters) Cancer Immunotherapy: A Roundtable Discussion (Jun 30 - reuters) Vical Provides Allovectin(R) and Herpes Simplex Vaccine Updates at BIO International... (Jun 28 - reuters) Building a Biotech Portfolio With High Potential Returns, Modest Risk (Jun 21 - reuters) Vical Presents Positive Correlation Between Response and Survival at ASCO for Completed... (Jun 06 - reuters) The Next Big Thing In Biotech: ASCO Stocks (Jun 04 - reuters) The Next Big Thing In Biotech: ASCO Stocks (Jun 03 - reuters) Vical to Present at Jefferies Global Healthcare Conference (Jun 02 - reuters) Careful Analysis Reveals Good Probability of Gains for Vical (Jun 02 - reuters) 5 Biotechs With Upcoming Clinical Trial Results (Jun 01 - reuters) Personalized Medicine for the Masses (May 25 - reuters) ASCO: Thursday's Cancer Stock Winners, Losers (May 19 - reuters) 4 Biotech Stocks with Extremely Bearish Options Sentiment (May 19 - reuters) Vical Presentations on TransVax(TM) and DNA Vaccines at ASGCT Conference (May 19 - reuters) ASCO: Traders Love Speculative Cancer Stocks (May 19 - reuters) 5 Biotech ASCO Abstracts to Watch (May 18 - reuters) 11 Potential Biotech Buy Out Targets (May 18 - reuters) Presentations by Vical and Collaborators at CMV/BetaHerpesvirus Workshop (May 16 - reuters) Vical to Present at Noble Financial Capital Markets Conference (May 10 - reuters) Vical to Present at Bank of America/Merrill Lynch Health Care Conference (May 09 - reuters) Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript (May 06 - reuters) Vical Reports First Quarter 2011 Financial Results and Progress in TransVax(TM) and... (May 05 - reuters) Vical and the University of Washington Receive Additional U.S. Patent for Herpes... (May 04 - reuters)

ADS

MY PORTFOLIO



GAIN vs LOSS


BEST vs WORST


SELECTION DIY

Market Cap
Last Trade
Gain/Loss
Webtech:
P / E
EPS
market cap / total revenue
TOT REV 1 / TOT REV 2
NET INC 1 / NET INC 2
MED NET INC / MED TOT REV
NET INCOME / MARKET CAP
totalRev1/totalRev3
net inc1/net inc3
tot rev 2/ tot rev 3
net inc 2 / net inc 3
.
MARKET CAP / NET TANGIBLE ASSETS
MARK CAP/TOT STOCK EQ
market cap / tot current assets
TOT CURR ASSETS / TOT LIAB
.
SELL HOLD BUY